Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
3 clinical trials · Condition
◉ Watch Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
| Record | Firm | Date |
|---|---|---|
| Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer (NCT03744793) | M.D. Anderson Cancer Center | 2019-04-11 |
| Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer (NCT03912818) | Stanford University | 2019-04-10 |
| Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery (NCT02812420) | M.D. Anderson Cancer Center | 2017-03-07 |
Track Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant automatically
Every clearance here is in the API, with alerts when new ones post.